Boston Scientific Corporation kicked off 2026 with a strong first quarter, posting net sales of $5.203 billion—up 11.6% on a reported basis and 9.4% on an operational and organic basis compared with the prior year period.
The performance topped the company’s guidance range and underscored continued momentum across its global medical technology portfolio.
Profitability surged sharply. GAAP net income attributable to common stockholders reached $1.341 billion, nearly doubling from $674 million, a year ago.
"Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems."
Growth was broad-based across segments. The MedSurg division rose 7.8% reported and 5.7% on an operational and organic basis, while Cardiovascular led the charge with 13.5% reported growth and 11.2% organic expansion.
International markets delivered double-digit gains across most regions. The U.S. grew 10.9%, EMEA posted 10.1% reported growth, APAC surged 14.7%, and Latin America and Canada led globally with 19.0% reported growth.
Beyond the numbers, Boston Scientific highlighted a wave of clinical and regulatory progress. Headline results included CHAMPION-AF, showing WATCHMAN FLX matched oral anticoagulants for efficacy while reducing bleeding risk, and HI-PEITHO, where EKOS™ plus anticoagulation outperformed anticoagulation alone in acute pulmonary embolism.
The company also reported positive long-term outcomes from its FARAPULSE pulsed field ablation platform, FDA clearance for its Asurys Fluid Management System, approval in China for the OPAL HDx Mapping System, and strong 24-month data for its Nalu Neurostimulation System in chronic pain.
Strategic expansion continued with the acquisition of Valencia Technologies, adding the eCoin® System for urge urinary incontinence, alongside new board appointments strengthening its financial and pharmaceutical leadership bench.
Looking ahead, Boston Scientific raised its full-year 2026 outlook, now projecting 7.0% to 8.5% reported sales growth and adjusted EPS of $3.34 to $3.41. For the second quarter, it forecasts revenue growth of 5.5% to 7.5% and adjusted EPS between $0.82 and $0.84—signaling sustained momentum into the year.
